Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutation-positive NSCLC”

233 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 233 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04765059
What this trial is testing

Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 98
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Not applicableLooking for participantsNCT07806604
What this trial is testing

Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Betta Pharmaceuticals Co., Ltd. 2,572
Testing effectiveness (Phase 2)Study completedNCT01580735
What this trial is testing

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd. 40
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Not applicableStudy completedNCT04640870
What this trial is testing

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Who this might be right for
Non Small Cell Lung CancerEGF-R Positive Non-Small Cell Lung CancerEGFR Gene Mutation
Hellenic Cooperative Oncology Group 59
Not applicableStudy completedNCT04105153
What this trial is testing

Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
Thoraxklinik-Heidelberg gGmbH 400
Early research (Phase 1)Study completedNCT04204473
What this trial is testing

TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

Who this might be right for
NSCLC
TYK Medicines, Inc 105
Large-scale testing (Phase 3)Looking for participantsNCT06970639
What this trial is testing

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Who this might be right for
NSCLC Patients With Brain Metastasis
Allist Pharmaceuticals, Inc. 380
Not applicableLooking for participantsNCT07696832
What this trial is testing

Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

Who this might be right for
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLCEGFR Mutation-negative and ALK Rearrangement-negativeEastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2+2 more
Guangdong Association of Clinical Trials
Testing effectiveness (Phase 2)Ended earlyNCT02580708
What this trial is testing

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 7
Post-approval studies (Phase 4)UnknownNCT01665417
What this trial is testing

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Who this might be right for
EGFR Positive Non-small Cell Lung CancerAdenocarcinoma
Betta Pharmaceuticals Co., Ltd. 100
Testing effectiveness (Phase 2)Looking for participantsNCT06109558
What this trial is testing

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Who this might be right for
Non Small Cell Lung CancerRET Gene MutationMET Amplification+1 more
Hunan Province Tumor Hospital 120
Testing effectiveness (Phase 2)Ended earlyNCT02485652
What this trial is testing

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 162
Early research (Phase 1)Ended earlyNCT03054038
What this trial is testing

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Carcinoma
Vanderbilt-Ingram Cancer Center 22
Not applicableStudy completedNCT03137264
What this trial is testing

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 44
Large-scale testing (Phase 3)UnknownNCT04028778
What this trial is testing

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

Who this might be right for
Lung Cancer, Nonsmall Cell
Sun Yat-sen University 310
Early research (Phase 1)Active Not RecruitingNCT03333343
What this trial is testing

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals 105
Testing effectiveness (Phase 2)Study completedNCT04184921
What this trial is testing

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 216
Testing effectiveness (Phase 2)UnknownNCT03460275
What this trial is testing

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 100
Next Page
265